Notice of Proposed Sale · 144
Mineralys Therapeutics, Inc.
MLYSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Mineralys Therapeutics, Inc.
- Issuer CIK
- 0001933414
- SEC file number
- 001-41614
- Phone
- (888) 378-6240
- Person for whose account securities are to be sold
- Warren Eric
- Relationships to issuer
- Officer
- Street
- 150 N. RADNOR CHESTER RD.
- Street (continued)
- SUITE F200
- City
- RADNOR
- State / country code
- PA
- Postal code
- 19087
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 7,438 | 199,884.80 | 82,498,101 | 07/21/2026 | NASDAQ | Merrill Lynch |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch
- Street
- 225 Liberty Street
- Street (continued)
- Floor 37
- City
- New York
- State / country code
- NY
- Postal code
- 10281
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 07/21/2026 | Exercise of employee stock options | Mineralys Therapeutics, Inc. | 7,438 | N | 07/21/2026 | Broker assisted cashless exercise |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Eric Warren | Common Stock | 06/26/2026 | 104,124 | 2,696,321.98 |
Seller — prior-sale row 1, entry 1
- Name
- Eric Warren
- Street
- 150 N. RADNOR CHESTER RD.
- Street (continued)
- SUITE F200
- City
- RADNOR
- State / country code
- PA
- Postal code
- 19087
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/21/2026
- Signed
- Eric Warren
- Plan adoption dates
- 03/27/2026
Company context
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.